Robert Blazej

About

is a Partner based in our San Francisco office. He invests in early stage life science companies and is responsible for coordination of firmwide diligence efforts on new investment opportunities. Robert currently holds board roles at Telo Therapeutics, Photoswitch BioSciences, and Dren Bio. Robert is a passionate biotechnologist with a diverse skill set spanning business, life science, engineering and intellectual property. He brings more than 10 years of small and big company operational experience to our team. As an entrepreneur, he co-founded Allopartis Biotechnologies out of QB3’s original “garage” incubator at UCSF and has been hooked on entrepreneurship ever since. Allopartis was acquired by Novozymes in 2013, becoming Novozymes’ Digital Biotechnology research site in San Francisco which Robert directed before joining Mission BioCapital in 2017.

Source (opens in a new tab)